Showing 1 - 8 results of 8 for search 'L. D. Latyntseva', query time: 0.01s Refine Results
  1. 1
    Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept

    Increment of the effectiveness of treating hypertension and dyslipidemia using a triple fixed-dose combination and the vascular age concept by O. V. Tsygankova, T. I. Batluk, L. D. Latyntseva

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    SUCCESSFUL CORRECTION OF REFRACTORY ARTERIAL HYPERTENSION AND MORBID OBESITY IN PATIENT WITH SEVERE OBSTRUCTIVE APNEA SYNDROME

    SUCCESSFUL CORRECTION OF REFRACTORY ARTERIAL HYPERTENSION AND MORBID OBESITY IN PATIENT WITH SEVERE OBSTRUCTIVE APNEA SYNDROME by O. V. Tsygankova, E. M. Kalinina, L. D. Latyntseva, M. I. Voevoda

    Published 2018-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Extended-release metformin in patients with prediabetes, chro­nic heart failure and abdominal obesity in light of the effect on fat depot compartments and glucose metabolism parameters

    Extended-release metformin in patients with prediabetes, chro­nic heart failure and abdominal obesity in light of the effect on fat depot compartments and glucose metabolism parame... by O. V. Tsygankova, N. E. Apartseva, L. D. Latyntseva, A. N. Ryabikov

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Legal and Medical Aspects of Off-Label Medication Use. Point of View

    Legal and Medical Aspects of Off-Label Medication Use. Point of View by O. V. Tsygankova, T. I. Batluk, L. D. Latyntseva, D. Y. Platonov, N. M. Akhmedzhanov

    Published 2019-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

    The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use by O. V. Tsygankova, L. D. Latyntseva, T. I. Batluk, D. Yu. Platonov, N. M. Akhmedzhanov

    Published 2019-12-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    In the Refractory Hypertension “Labyrinth”. Focus on Primary Hyperaldosteronism

    In the Refractory Hypertension “Labyrinth”. Focus on Primary Hyperaldosteronism by O. V. Tsygankova, T. I. Batluk, L. D. Latyntseva, E. V. Akhmerova, N. M. Akhmedzhanov

    Published 2020-09-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Insulin resistance and heart failure with preserved ejection fraction. Pathogenetic and therapeutic crossroads

    Insulin resistance and heart failure with preserved ejection fraction. Pathogenetic and therapeutic crossroads by O. V. Tsygankova, N. E. Evdokimova, V. V. Veretyuk, L. D. Latyntseva, A. S. Ametov

    Published 2023-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Effect of extended-release metformin on humoral cardiometabolic markers and lipid peroxidation parameters in patients with prediabetes, heart failure with preserved ejection fraction and abdominal obesity

    Effect of extended-release metformin on humoral cardiometabolic markers and lipid peroxidation parameters in patients with prediabetes, heart failure with preserved ejection fracti... by O. V. Tsygankova, N. E. Apartseva, L. D. Latyntseva, Ya. V. Polonskaya, E. V. Kashtanova

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: